Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithm™ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































332.486M
















395.686M




















196.689B
























211.605B






























































150.448B

































Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




12/12/2017: $MYGN Myriad Genetics announced that data from the EMBRACA trial showed Myriad's BRACAnalysis CDx test successfully identified patients with metastatic breast cancer who responded to Pfizer's (PFE) investigational PARP inhibitor, talazoparib. -- Go to this Pulse Post



12/11/2017: $LLY Eli Lilly reported top-line results from Ph 3 RAINFALL study of CYRAMZA in first-line advanced gastric cancer - met primary endpoint but results highlight challenges associated with improving outcomes for people with advanced gastric cancer. -- Go to this Pulse Post



12/11/2017: $CVM CEL-SCI Corp reached full enrollment in the pivotal Phase 3 head and neck cancer study of Multikine. -- Go to this Pulse Post



12/11/2017: $RNN Rexahn Pharmaceuticals presented preclinical data on the efficacy of Supinoxin alone and in combination with immunotherapy; Supinoxin shows potent activity against patient-derived triple negative breast cancer tumors in preclinical models. -- Go to this Pulse Post



12/08/2017: $RDUS Radius Health details recent elacestrant data presentations; to discontinue further evaluation for vasomotor symptoms to focus on development as breast cancer treatment - to host call at 9pm ET. -- Go to this Pulse Post



12/08/2017: $LLY Eli Lilly reported top-line results from Ph 3 RAINFALL study of CYRAMZA in first-line advanced gastric cancer - met primary endpoint but results highlight challenges associated with improving outcomes for people with advanced gastric cancer. -- Go to this Pulse Post



12/07/2017: $MYGN Myriad Genetics presented pivotal validation study for new riskScore test; demonstrated highly statistically-significant ability to predict 5-year and lifetime risk of breast cancer in women who test negative for hereditary breast cancer mutations. -- Go to this Pulse Post



12/07/2017: $RDUS Radius Health details recent elacestrant data presentations; to discontinue further evaluation for vasomotor symptoms to focus on development as breast cancer treatment - to host call at 9pm ET. -- Go to this Pulse Post



12/07/2017: $CELG Celgene announced survival results from the GeparSepto clinical trial comparing the investigational use of ABRAXANE to paclitaxel in early high-risk breast cancer patients at the 2017 SABCS. -- Go to this Pulse Post



12/07/2017: $SYRS Syros Pharmaceuticals announced new preclinical data on SY-1365 'demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response. -- Go to this Pulse Post



12/07/2017: $DSNKY Daiichi Sankyo presented updated safety and efficacy data from two subgroups of patients with metastatic breast cancer from an ongoing phase 1 study of DS-8201. -- Go to this Pulse Post



12/07/2017: $CVM CEL-SCI Corp: IDMC for its Phase 3 head and neck cancer study of its investigational immunotherapy Multikine has completed its review of the Phase 3 study data, recommends continuing the study. -- Go to this Pulse Post



12/06/2017: $MYGN Myriad Genetics presented pivotal validation study for new riskScore test; demonstrated highly statistically-significant ability to predict 5-year and lifetime risk of breast cancer in women who test negative for hereditary breast cancer mutations. -- Go to this Pulse Post



12/06/2017: $GHDX Genomic Health today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals, subsidiary of Johnson and Johnson, to evaluate the Oncotype DX Genomic Prostate Score test for their prostate cancer drug pipeline. -- Go to this Pulse Post



12/05/2017: $ICFI ICF International awarded $9M cancer surveillance task order from the Centered for Disease Control and Prevention. -- Go to this Pulse Post



12/04/2017: $ICFI ICF International awarded $9M cancer surveillance task order from the Centered for Disease Control and Prevention. -- Go to this Pulse Post



11/28/2017: $GHDX Genomic Health announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics' IsoPSA reagents and technology. -- Go to this Pulse Post



11/28/2017: $ITUS ITUS announced that the United States Patent and Trademark Office issued a Notice of Allowance on the second patent filed by the company to protect its cancer detection technology. -- Go to this Pulse Post



11/27/2017: $INO Inovio Pharma 'demonstrated the synergistic effect of combining Inovio's TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. -- Go to this Pulse Post



11/21/2017: $ITUS ITUS reminds that it will be holding a conference call today at 5 p.m. Eastern to discuss the launch of its Chimeric Antigen Receptor T-Cell (CAR-T) cancer therapeutics program. -- Go to this Pulse Post



11/20/2017: $JNJ Johnson & Johnson: EC granted approval to broaden the existing marketing authorisation for ZYTIGA plus prednisone / prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. -- Go to this Pulse Post



11/20/2017: $RHHBY Roche up 6% in Switzerland following positive lung cancer combo data, creating a competitive threat to Merck (MRK), down 1.7% premarket. -- Go to this Pulse Post



11/14/2017: $AZN AstraZeneca: EC has approved a new indication for Faslodex in combination w/ palbociclib for the treatment of HR+, HER2- locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. -- Go to this Pulse Post



11/14/2017: $MCRB Seres Therapeutics, MD Anderson, and the Parker Institute announce 'collaboration to evaluate the potential of Seres' microbiome therapies to improve the outcomes of cancer patients treated with currently-available immunotherapy. -- Go to this Pulse Post



11/13/2017: $LPTX Leap Therapeutics announced first patient dosed with DKN-01 and KEYTRUDA (pembrolizumab) in Esophagogastric cancer trial. -- Go to this Pulse Post



11/13/2017: $RXII RXi Pharma and Gustave Roussy enter into a collaborative research agreement to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments. -- Go to this Pulse Post



11/10/2017: $INO Inovio Pharma announced two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. -- Go to this Pulse Post



11/07/2017: $RHHBY Roche Hldg obtains FDA approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Roche medicine ALECENSA. -- Go to this Pulse Post



11/01/2017: $SKLN Skyline Medical announced a strategic collaboration to use the Helomics D-CHIP platform to develop new approaches for personalized cancer diagnosis and care. -- Go to this Pulse Post



11/01/2017: $VCYT Veracyte announced that data from a prospective clinical utility study show that use of the company's Percepta Bronchial Genomic Classifier reduced invasive procedures by greater than 50 percent in lung cancer screening and diagnosis. -- Go to this Pulse Post